SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Meta Expands AI Training With Employee Activity Tracking Tools 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
BOSTON, March 22, 2017 -- Block & Leviton LLP (www.blockesq.com), a Boston-based securities litigation firm representing investors nationwide, reminds investors of PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKTS:PXRB) of the March 27, 2017 lead plaintiff deadline.
If you purchased PixarBio securities in either the Company’s private placement, or on the open market between October 31, 2016 and January 20, 2017, you are encouraged to contact attorney Bradley Vettraino at (617) 398-5600, by email at [email protected], or by visiting www.blockesq.com/pixarbio.
On January 3, 2017, PixarBio's CEO announced a purported attempt by the Company to acquire InVivo Therapeutics Holdings Corp. ("InVivo") in a $100 million takeover bid. InVivo refuted PixarBio’s purported offer as "not credible." On January 23, 2017, the SEC announced that it had halted trading in the securities of PixarBio, citing concerns about possible "manipulative or deceptive activities" in the market for the Company's stock.
PixarBio’s stock plunged more than 35% during the month of January, causing tens of millions in losses to investors.
The lawsuit subsequently filed by Block & Leviton against PixarBio and its CEO, in the United States District Court for Massachusetts alleges that Defendants failed to disclose and/or made false and/or misleading statements regarding: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; (3) the company’s current and prospective development efforts, and (4) that, as a result, the Company’s business, operations, and prospects, were false and misleading.
As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.
Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.
This notice may constitute attorney advertising.
CONTACT: Block & Leviton LLP Bradley J. Vettraino 155 Federal Street, Suite 400 Boston, MA 02110 (617) 398-5600 [email protected]
